NO972176L - Konjugater av BDNF og NT-3 med en vannopplöselig polymer - Google Patents

Konjugater av BDNF og NT-3 med en vannopplöselig polymer

Info

Publication number: NO972176L
Authority: NO; Norway
Prior art keywords: bdnf; polypeptide; polyethylene glycol; water; soluble polymer
Prior art date: 1994-11-14

Application number

NO972176A

Other languages

English (en)

Norwegian (no)

Other versions

NO972176D0 (no

Inventor

Olaf F Kinstler

Qiao Yan

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-11-14

Filing date

1997-05-12

Publication date

1997-07-14

1997-05-12 Application filed by Amgen Inc filed Critical Amgen Inc

1997-05-12 Publication of NO972176D0 publication Critical patent/NO972176D0/no

1997-07-14 Publication of NO972176L publication Critical patent/NO972176L/no

Links

108090000715 Brain-derived neurotrophic factor Proteins 0.000 title claims description 124
102000004219 Brain-derived neurotrophic factor Human genes 0.000 title claims description 124
229920003169 water-soluble polymer Polymers 0.000 title claims description 33
239000002202 Polyethylene glycol Substances 0.000 claims description 66
229920001223 polyethylene glycol Polymers 0.000 claims description 66
102000004196 processed proteins & peptides Human genes 0.000 claims description 64
108090000765 processed proteins & peptides Proteins 0.000 claims description 64
229920001184 polypeptide Polymers 0.000 claims description 63
238000000034 method Methods 0.000 claims description 43
229920000642 polymer Polymers 0.000 claims description 41
238000002360 preparation method Methods 0.000 claims description 21
238000005932 reductive alkylation reaction Methods 0.000 claims description 18
210000002161 motor neuron Anatomy 0.000 claims description 15
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 12
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 12
-1 poly(N-vinylpyrrolidone) Polymers 0.000 claims description 9
238000001727 in vivo Methods 0.000 claims description 7
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
210000005013 brain tissue Anatomy 0.000 claims description 6
210000004027 cell Anatomy 0.000 claims description 6
239000003638 chemical reducing agent Substances 0.000 claims description 5
229920001577 copolymer Polymers 0.000 claims description 5
229920001451 polypropylene glycol Polymers 0.000 claims description 5
229920002307 Dextran Polymers 0.000 claims description 4
229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
235000019422 polyvinyl alcohol Nutrition 0.000 claims description 4
125000002252 acyl group Chemical group 0.000 claims description 3
125000003172 aldehyde group Chemical group 0.000 claims description 3
239000007795 chemical reaction product Substances 0.000 claims description 3
229920001519 homopolymer Polymers 0.000 claims description 3
229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 claims description 3
229920001583 poly(oxyethylated polyols) Polymers 0.000 claims description 3
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 claims description 3
230000001580 bacterial effect Effects 0.000 claims description 2
230000008569 process Effects 0.000 claims description 2
230000002378 acidificating effect Effects 0.000 claims 2
230000005012 migration Effects 0.000 claims 1
238000013508 migration Methods 0.000 claims 1
102000004230 Neurotrophin 3 Human genes 0.000 description 59
108090000742 Neurotrophin 3 Proteins 0.000 description 59
229940032018 neurotrophin 3 Drugs 0.000 description 51
102000004169 proteins and genes Human genes 0.000 description 24
108090000623 proteins and genes Proteins 0.000 description 24
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
108010058699 Choline O-acetyltransferase Proteins 0.000 description 18
102100023460 Choline O-acetyltransferase Human genes 0.000 description 18
238000005917 acylation reaction Methods 0.000 description 18
238000006243 chemical reaction Methods 0.000 description 18
230000010933 acylation Effects 0.000 description 15
239000000047 product Substances 0.000 description 15
238000011282 treatment Methods 0.000 description 15
241000700159 Rattus Species 0.000 description 14
230000001815 facial effect Effects 0.000 description 14
230000006320 pegylation Effects 0.000 description 14
241001465754 Metazoa Species 0.000 description 11
150000001299 aldehydes Chemical class 0.000 description 10
239000000203 mixture Substances 0.000 description 10
239000002953 phosphate buffered saline Substances 0.000 description 10
239000011780 sodium chloride Substances 0.000 description 10
239000001488 sodium phosphate Substances 0.000 description 10
229910000162 sodium phosphate Inorganic materials 0.000 description 10
230000001225 therapeutic effect Effects 0.000 description 10
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 10
238000005804 alkylation reaction Methods 0.000 description 9
210000004556 brain Anatomy 0.000 description 9
230000004071 biological effect Effects 0.000 description 8
239000000539 dimer Substances 0.000 description 8
238000000338 in vitro Methods 0.000 description 8
210000002569 neuron Anatomy 0.000 description 8
238000001542 size-exclusion chromatography Methods 0.000 description 8
230000029936 alkylation Effects 0.000 description 7
125000003277 amino group Chemical group 0.000 description 7
238000001212 derivatisation Methods 0.000 description 7
150000002148 esters Chemical class 0.000 description 7
239000011541 reaction mixture Substances 0.000 description 7
239000000243 solution Substances 0.000 description 7
241000894007 species Species 0.000 description 7
108010025020 Nerve Growth Factor Proteins 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
230000000694 effects Effects 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
230000009467 reduction Effects 0.000 description 6
238000006722 reduction reaction Methods 0.000 description 6
239000012064 sodium phosphate buffer Substances 0.000 description 6
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
239000004472 Lysine Substances 0.000 description 5
238000003364 immunohistochemistry Methods 0.000 description 5
238000001802 infusion Methods 0.000 description 5
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 5
230000004048 modification Effects 0.000 description 5
238000012986 modification Methods 0.000 description 5
210000001577 neostriatum Anatomy 0.000 description 5
230000035515 penetration Effects 0.000 description 5
230000009145 protein modification Effects 0.000 description 5
238000010186 staining Methods 0.000 description 5
210000003523 substantia nigra Anatomy 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
229920002684 Sepharose Polymers 0.000 description 4
238000000692 Student's t-test Methods 0.000 description 4
230000037396 body weight Effects 0.000 description 4
239000000872 buffer Substances 0.000 description 4
230000002354 daily effect Effects 0.000 description 4
231100000673 dose–response relationship Toxicity 0.000 description 4
210000000256 facial nerve Anatomy 0.000 description 4
230000006870 function Effects 0.000 description 4
125000003827 glycol group Chemical group 0.000 description 4
238000005342 ion exchange Methods 0.000 description 4
210000003594 spinal ganglia Anatomy 0.000 description 4
238000012360 testing method Methods 0.000 description 4
239000003981 vehicle Substances 0.000 description 4
CXCHEKCRJQRVNG-UHFFFAOYSA-N 2,2,2-trifluoroethanesulfonyl chloride Chemical compound FC(F)(F)CS(Cl)(=O)=O CXCHEKCRJQRVNG-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
125000000729 N-terminal amino-acid group Chemical group 0.000 description 3
102000015336 Nerve Growth Factor Human genes 0.000 description 3
102000007072 Nerve Growth Factors Human genes 0.000 description 3
229930040373 Paraformaldehyde Natural products 0.000 description 3
230000008901 benefit Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
230000003902 lesion Effects 0.000 description 3
238000012423 maintenance Methods 0.000 description 3
229940053128 nerve growth factor Drugs 0.000 description 3
230000004770 neurodegeneration Effects 0.000 description 3
208000015122 neurodegenerative disease Diseases 0.000 description 3
229920002866 paraformaldehyde Polymers 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
239000008223 sterile water Substances 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
230000007306 turnover Effects 0.000 description 3
206010002091 Anaesthesia Diseases 0.000 description 2
241001573498 Compacta Species 0.000 description 2
241000287828 Gallus gallus Species 0.000 description 2
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 2
108091006006 PEGylated Proteins Proteins 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
238000000540 analysis of variance Methods 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
238000010171 animal model Methods 0.000 description 2
125000004104 aryloxy group Chemical group 0.000 description 2
239000007998 bicine buffer Substances 0.000 description 2
238000004166 bioassay Methods 0.000 description 2
210000005056 cell body Anatomy 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
238000002523 gelfiltration Methods 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
230000006872 improvement Effects 0.000 description 2
238000011835 investigation Methods 0.000 description 2
125000005647 linker group Chemical group 0.000 description 2
239000000463 material Substances 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
230000014511 neuron projection development Effects 0.000 description 2
239000003900 neurotrophic factor Substances 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
238000006116 polymerization reaction Methods 0.000 description 2
229940124606 potential therapeutic agent Drugs 0.000 description 2
238000011002 quantification Methods 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000007441 retrograde transport Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
238000012353 t test Methods 0.000 description 2
230000001228 trophic effect Effects 0.000 description 2
210000004515 ventral tegmental area Anatomy 0.000 description 2
AASBXERNXVFUEJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) propanoate Chemical compound CCC(=O)ON1C(=O)CCC1=O AASBXERNXVFUEJ-UHFFFAOYSA-N 0.000 description 1
WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
APRZHQXAAWPYHS-UHFFFAOYSA-N 4-[5-[3-(carboxymethoxy)phenyl]-3-(4,5-dimethyl-1,3-thiazol-2-yl)tetrazol-3-ium-2-yl]benzenesulfonate Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=C(OCC(O)=O)C=CC=2)=NN1C1=CC=C(S([O-])(=O)=O)C=C1 APRZHQXAAWPYHS-UHFFFAOYSA-N 0.000 description 1
125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
102000055025 Adenosine deaminases Human genes 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
108010041884 CD4 Immunoadhesins Proteins 0.000 description 1
241000283707 Capra Species 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102000004547 Glucosylceramidase Human genes 0.000 description 1
108010017544 Glucosylceramidase Proteins 0.000 description 1
206010019196 Head injury Diseases 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000739876 Homo sapiens Brain-derived neurotrophic factor Proteins 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
101800000135 N-terminal protein Proteins 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
101800001452 P1 proteinase Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
201000007737 Retinal degeneration Diseases 0.000 description 1
239000002262 Schiff base Substances 0.000 description 1
150000004753 Schiff bases Chemical class 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
102000019197 Superoxide Dismutase Human genes 0.000 description 1
108010012715 Superoxide dismutase Proteins 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
102000004357 Transferases Human genes 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
229960005054 acepromazine Drugs 0.000 description 1
230000004913 activation Effects 0.000 description 1
229940060205 adagen Drugs 0.000 description 1
238000007792 addition Methods 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
125000003275 alpha amino acid group Chemical group 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
238000013103 analytical ultracentrifugation Methods 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
229940088623 biologically active substance Drugs 0.000 description 1
RJTANRZEWTUVMA-UHFFFAOYSA-N boron;n-methylmethanamine Chemical compound [B].CNC RJTANRZEWTUVMA-UHFFFAOYSA-N 0.000 description 1
NNTOJPXOCKCMKR-UHFFFAOYSA-N boron;pyridine Chemical compound [B].C1=CC=NC=C1 NNTOJPXOCKCMKR-UHFFFAOYSA-N 0.000 description 1
210000000133 brain stem Anatomy 0.000 description 1
108010046910 brain-derived growth factor Proteins 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000030833 cell death Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
230000001713 cholinergic effect Effects 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
239000002872 contrast media Substances 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000003795 desorption Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
210000005064 dopaminergic neuron Anatomy 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
238000001641 gel filtration chromatography Methods 0.000 description 1
102000034238 globular proteins Human genes 0.000 description 1
108091005896 globular proteins Proteins 0.000 description 1
125000003147 glycosyl group Chemical group 0.000 description 1
239000011544 gradient gel Substances 0.000 description 1
210000004884 grey matter Anatomy 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
239000008241 heterogeneous mixture Substances 0.000 description 1
102000051542 human BDNF Human genes 0.000 description 1
229940077456 human brain-derived neurotrophic factor Drugs 0.000 description 1
150000002463 imidates Chemical class 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000002055 immunohistochemical effect Effects 0.000 description 1
238000012744 immunostaining Methods 0.000 description 1
239000007943 implant Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000010354 integration Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000007914 intraventricular administration Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
229960004184 ketamine hydrochloride Drugs 0.000 description 1
229920001427 mPEG Polymers 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
108091005573 modified proteins Proteins 0.000 description 1
102000035118 modified proteins Human genes 0.000 description 1
229940126619 mouse monoclonal antibody Drugs 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
238000010984 neurological examination Methods 0.000 description 1
210000004179 neuropil Anatomy 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
229920000620 organic polymer Polymers 0.000 description 1
230000037361 pathway Effects 0.000 description 1
238000012510 peptide mapping method Methods 0.000 description 1
210000000578 peripheral nerve Anatomy 0.000 description 1
208000027232 peripheral nervous system disease Diseases 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
238000009520 phase I clinical trial Methods 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
229920001308 poly(aminoacid) Polymers 0.000 description 1
210000004896 polypeptide structure Anatomy 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
238000000734 protein sequencing Methods 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
229920005604 random copolymer Polymers 0.000 description 1
239000000376 reactant Substances 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004258 retinal degeneration Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
238000005185 salting out Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
208000002491 severe combined immunodeficiency Diseases 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
238000013223 sprague-dawley female rat Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000011421 subcutaneous treatment Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/839—Nerves; brain

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Zoology (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Treatment Of Sludge (AREA)
Treatment Of Water By Ion Exchange (AREA)
Physical Or Chemical Processes And Apparatus (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pyrrole Compounds (AREA)
Hydrogenated Pyridines (AREA)
Detergent Compositions (AREA)
Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

NO972176A 1994-11-14 1997-05-12 Konjugater av BDNF og NT-3 med en vannopplöselig polymer NO972176L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/340,131 US5770577A (en)	1994-11-14	1994-11-14	BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
PCT/US1995/014658 WO1996015146A1 (en)	1994-11-14	1995-11-13	Conjugates of bdnf and nt-3 with a water-soluble polymer

Publications (2)

Publication Number	Publication Date
NO972176D0 NO972176D0 (no)	1997-05-12
NO972176L true NO972176L (no)	1997-07-14

Family

ID=23332020

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO972176A NO972176L (no)	1994-11-14	1997-05-12	Konjugater av BDNF og NT-3 med en vannopplöselig polymer

Country Status (22)

Country	Link
US (1)	US5770577A (de)
EP (1)	EP0792288B1 (de)
JP (1)	JPH10508853A (de)
KR (1)	KR100253762B1 (de)
CN (1)	CN1173183A (de)
AT (1)	ATE175973T1 (de)
AU (1)	AU694589B2 (de)
CA (1)	CA2204640C (de)
CZ (1)	CZ137597A3 (de)
DE (1)	DE69507507T2 (de)
DK (1)	DK0792288T3 (de)
ES (1)	ES2126331T3 (de)
GR (1)	GR3029790T3 (de)
HU (1)	HUT77747A (de)
IL (1)	IL115965A (de)
MX (1)	MX9703362A (de)
NO (1)	NO972176L (de)
NZ (1)	NZ296452A (de)
RU (1)	RU2136694C1 (de)
SK (1)	SK283083B6 (de)
WO (1)	WO1996015146A1 (de)
ZA (1)	ZA959653B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5824784A (en) *	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
JPH10212241A (ja) *	1996-05-27	1998-08-11	Sumitomo Pharmaceut Co Ltd	Ｂｄｎｆを安定に含有する製剤
AU720232B2 (en)	1996-07-19	2000-05-25	Amgen, Inc.	Analogs of cationic proteins
EP1126869B1 (de) *	1998-10-28	2008-09-03	Cornell Research Foundation, Inc.	Methoden zur regulierung der angiogenese und vaskuläre integrität mittels trk rezeptor liganden bdnf, nt-3 und nt-4
US6656474B1 (en) *	1999-01-15	2003-12-02	Regeneron Pharmaceuticals, Inc.	Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders
RU2290411C2 (ru) *	2000-01-10	2006-12-27	Максиджен Холдингз Лтд	Конъюгаты g-csf
US6800607B2 (en) *	2000-02-29	2004-10-05	Ltt Bio-Pharma Co., Ltd.	Modified BDNF
US7514239B2 (en) *	2000-03-28	2009-04-07	Amgen Inc.	Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
US6586398B1 (en)	2000-04-07	2003-07-01	Amgen, Inc.	Chemically modified novel erythropoietin stimulating protein compositions and methods
PL211162B1 (pl) *	2001-02-01	2012-04-30	Biogen Idec Inc	Polipeptyd wariantu neublastyny, zawierające go białko fuzyjne i sposób ich wytwarzania oraz dimer, kwas nukleinowy, wektor, komórka gospodarza, koniugat, kompozycja farmaceutyczna i zastosowanie
US7442370B2 (en) *	2001-02-01	2008-10-28	Biogen Idec Ma Inc.	Polymer conjugates of mutated neublastin
WO2002069232A2 (en)	2001-02-19	2002-09-06	Merck Patent Gmbh	Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
EP1234583A1 (de) *	2001-02-23	2002-08-28	F. Hoffmann-La Roche Ag	PEG-Konjugate des HGF-NK4
US7276580B2 (en) *	2001-03-12	2007-10-02	Biogen Idec Ma Inc.	Neurotrophic factors
RU2307126C2 (ru) *	2001-07-11	2007-09-27	Максиджен Холдингз Лтд.	Конъюгаты g-csf
CN1671769B (zh) *	2002-07-24	2010-05-12	弗·哈夫曼-拉罗切有限公司	聚乙二醇醛衍生物
JP4571776B2 (ja) *	2002-11-05	2010-10-27	Ｊｘ日鉱日石エネルギー株式会社	潤滑油組成物
RS20050502A (sr) *	2002-12-26	2007-08-03	Mountain View Pharmaceuticals Inc.,	Polimerni konjugati interferona- beta sa povećanom biološkom aktivnošću
PL396711A1 (pl) *	2002-12-26	2011-12-19	Mountain View Pharmaceuticals, Inc.	Koniugaty polimerów z cytokinami, chemokinami, czynnikami wzrostu, hormonami polipeptydowymi i ich antagonistami, kompozycja farmaceutyczna i sposób zapobiegania, diagnozowania lub leczenia
PL383683A1 (pl) *	2003-01-31	2008-04-14	Biogen Idec Ma Inc.	Koniugaty polimerowe zmutowanej neublastyny
EP2902491A1 (de)	2003-03-19	2015-08-05	Biogen MA Inc.	NOGO Rezeptor bindendes Protein
JP4742030B2 (ja)	2003-04-18	2011-08-10	バイオジェン・アイデック・エムエイ・インコーポレイテッド	ポリマーが結合したグリコシル化ニューブラスチン
JP2007523196A (ja) *	2004-02-20	2007-08-16	ライナットニューロサイエンスコーポレイション	Ｎｔ−４／５を用いて肥満または糖尿病を処置する方法
EP1776136B1 (de)	2004-06-24	2012-10-03	Biogen Idec MA Inc.	Behandlung von entmyelinisierenden erkrankungen
ATE472333T1 (de)	2004-08-19	2010-07-15	Biogen Idec Inc	Rückfaltung von proteinen der transforming-growth-factor-beta-familie
JP4852545B2 (ja) *	2004-08-19	2012-01-11	バイオジェン・アイデック・エムエイ・インコーポレイテッド	ニューブラスチン（Ｎｅｕｂｌａｓｔｉｎ）変異体
GT200600240A (es)	2005-06-06	2007-03-14		Anticuerpos monoclonales anti-trkb y usos de los mismos
AU2006269458B2 (en)	2005-07-08	2012-11-08	Biogen Ma Inc.	Sp35 antibodies and uses thereof
ITRM20050447A1 (it) *	2005-08-19	2007-02-20	Anabasis S R L	Uso del nerve growth factor in collirio nella terapia di patologie del sistema nervoso centrale, quali la malattia di alzheimer e il morbo di parkinson.
US7935342B2 (en) *	2006-02-02	2011-05-03	Rinat Neuroscience Corp.	Methods for treating obesity by administering a trkB antagonist
EP1988923A1 (de) *	2006-02-02	2008-11-12	Rinat Neuroscience Corp.	Verfahren zur behandlung von unerwünschtem gewichtsverlust oder essstörungen durch verabreichung eines trkb-agonisten
TWI501774B (zh)	2006-02-27	2015-10-01	Biogen Idec Inc	神經性病症之治療
ES2450065T3 (es) *	2006-03-01	2014-03-21	Biogen Idec Ma Inc.	Composiciones y métodos para la administración de proteínas de la familia de ligandos del GDNF
US8377448B2 (en) *	2006-05-15	2013-02-19	The Board Of Trustees Of The Leland Standford Junior University	CD47 related compositions and methods for treating immunological diseases and disorders
WO2007133811A2 (en) *	2006-05-15	2007-11-22	Viral Logic Systems Technology Corp.	Cd47 related compositions and methods for treating immunological diseases and disorders
BRPI0720473A2 (pt) *	2006-12-20	2014-01-14	Rinat Neuroscience Corp	Agonistas de trkb para tratamento de distúbios autoimunes
JP5583005B2 (ja)	2007-05-01	2014-09-03	バイオジェン・アイデック・エムエイ・インコーポレイテッド	血管新生を増大させるための組成物および方法
EP2205634A2 (de) *	2007-08-08	2010-07-14	Biogen Idec MA, Inc.	Anti-neublastin-antikörper und anwendungen davon
CA2701189C (en) *	2007-10-11	2017-05-16	Biogen Idec Ma Inc.	Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists
JP5754046B2 (ja) *	2007-11-08	2015-07-22	バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎＭＡＩｎｃ．	脱髄を伴う状態の治療におけるｌｉｎｇｏ−４アンタゴニストの使用
DK2982695T3 (da)	2008-07-09	2019-05-13	Biogen Ma Inc	Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
RU2013103763A (ru)	2010-07-02	2014-08-10	Ангиохем Инк.	Короткие и содержащие d-аминокислоты полипептиды для терапевтических конъюгатов и их применения
NZ702178A (en)	2012-05-14	2017-01-27	Biogen Ma Inc	Lingo-2 antagonists for treatment of conditions involving motor neurons
CN102964442B (zh) *	2012-11-19	2015-04-29	未名生物医药有限公司	一种聚乙二醇同神经生长因子结合物的制备方法
WO2016112270A1 (en)	2015-01-08	2016-07-14	Biogen Ma Inc.	Lingo-1 antagonists and uses for treatment of demyelinating disorders
CN111514279B (zh) *	2020-06-16	2023-07-18	温州医科大学附属第二医院（温州医科大学附属育英儿童医院）	神经营养因子3在制备治疗男性性腺功能减退症的药物中的应用
CN115025723A (zh) *	2022-05-10	2022-09-09	吉林大学	经神经生长因子及多巴胺改良的peg-plga微球

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4179337A (en) *	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4002531A (en) *	1976-01-22	1977-01-11	Pierce Chemical Company	Modifying enzymes with polyethylene glycol and product produced thereby
US5169762A (en) *	1983-03-03	1992-12-08	Genentech, Inc.	Human nerve growth factor by recombinant technology
EP0154316B1 (de) *	1984-03-06	1989-09-13	Takeda Chemical Industries, Ltd.	Chemisch modifizierte Lymphokine und Verfahren zu ihrer Herstellung
GB8430252D0 (en) *	1984-11-30	1985-01-09	Beecham Group Plc	Compounds
US4904584A (en) *	1987-12-23	1990-02-27	Genetics Institute, Inc.	Site-specific homogeneous modification of polypeptides
CA1340810C (en) *	1988-03-31	1999-11-02	Motoo Yamasaki	Polypeptide derivatives of human granulocyte colony stimulating factor
JP2989002B2 (ja) *	1988-12-22	1999-12-13	キリン―アムジエン・インコーポレーテツド	化学修飾顆粒球コロニー刺激因子
US5180820A (en) *	1989-08-30	1993-01-19	Barde Yves Alain	Brain-derived neurotrophic factor
US5229500A (en) *	1989-08-30	1993-07-20	Regeneron Pharmaceuticals, Inc.	Brain derived neurotrophic factor
IL95511A (en) *	1989-08-30	2000-10-31	Max Planck Gesellschaft	Neurotrophin-3 a novel neurotrophic factor related to nerve growth and brain derived neurotrophic factor
US5182107A (en) *	1989-09-07	1993-01-26	Alkermes, Inc.	Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
JPH04218000A (ja) *	1990-02-13	1992-08-07	Kirin Amgen Inc	修飾ポリペプチド
IE912365A1 (en) *	1990-07-23	1992-01-29	Zeneca Ltd	Continuous release pharmaceutical compositions
DK0550665T3 (da) *	1990-09-25	1996-12-02	Genentech Inc	Ny neurotrofisk faktor
US5252714A (en) *	1990-11-28	1993-10-12	The University Of Alabama In Huntsville	Preparation and use of polyethylene glycol propionaldehyde
US5389529A (en) *	1991-06-12	1995-02-14	Regeneron Pharmaceuticals, Inc.	Modified lamβ signal sequence and processes for producing recombinant neurotrophins
NZ244778A (en) *	1991-10-21	1994-03-25	Ortho Pharma Corp	Peg imidates and protein derivatives thereof
US5260308A (en) *	1991-11-06	1993-11-09	Mayo Foundation For Medical Education And Research	Method to increase permeability of the blood-nerve/brain barriers to proteins
US5468872A (en) *	1993-09-16	1995-11-21	Cephalon, Inc.	K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders

1994
- 1994-11-14 US US08/340,131 patent/US5770577A/en not_active Expired - Lifetime
1995
- 1995-11-12 IL IL11596595A patent/IL115965A/en active IP Right Grant
- 1995-11-13 CZ CZ971375A patent/CZ137597A3/cs unknown
- 1995-11-13 SK SK571-97A patent/SK283083B6/sk unknown
- 1995-11-13 RU RU97107892/04A patent/RU2136694C1/ru not_active IP Right Cessation
- 1995-11-13 WO PCT/US1995/014658 patent/WO1996015146A1/en not_active Ceased
- 1995-11-13 MX MX9703362A patent/MX9703362A/es not_active IP Right Cessation
- 1995-11-13 AT AT95939123T patent/ATE175973T1/de not_active IP Right Cessation
- 1995-11-13 DK DK95939123T patent/DK0792288T3/da active
- 1995-11-13 NZ NZ296452A patent/NZ296452A/xx unknown
- 1995-11-13 HU HU9800671A patent/HUT77747A/hu unknown
- 1995-11-13 AU AU41071/96A patent/AU694589B2/en not_active Ceased
- 1995-11-13 KR KR1019970703211A patent/KR100253762B1/ko not_active Expired - Fee Related
- 1995-11-13 JP JP8516219A patent/JPH10508853A/ja not_active Ceased
- 1995-11-13 CN CN95197321A patent/CN1173183A/zh active Pending
- 1995-11-13 EP EP95939123A patent/EP0792288B1/de not_active Expired - Lifetime
- 1995-11-13 DE DE69507507T patent/DE69507507T2/de not_active Expired - Lifetime
- 1995-11-13 CA CA002204640A patent/CA2204640C/en not_active Expired - Fee Related
- 1995-11-13 ES ES95939123T patent/ES2126331T3/es not_active Expired - Lifetime
- 1995-11-14 ZA ZA9509653A patent/ZA959653B/xx unknown
1997
- 1997-05-12 NO NO972176A patent/NO972176L/no not_active Application Discontinuation
1999
- 1999-03-23 GR GR990400878T patent/GR3029790T3/el unknown

Also Published As

Publication number	Publication date
ZA959653B (en)	1997-08-26
JPH10508853A (ja)	1998-09-02
SK283083B6 (sk)	2003-02-04
NO972176D0 (no)	1997-05-12
DE69507507T2 (de)	1999-05-27
CA2204640A1 (en)	1996-05-23
MX9703362A (es)	1997-08-30
SK57197A3 (en)	1999-02-11
AU4107196A (en)	1996-06-06
IL115965A (en)	2001-01-28
CN1173183A (zh)	1998-02-11
HUT77747A (hu)	1998-07-28
ES2126331T3 (es)	1999-03-16
NZ296452A (en)	1999-01-28
CA2204640C (en)	2001-01-09
EP0792288A1 (de)	1997-09-03
IL115965A0 (en)	1996-01-31
RU2136694C1 (ru)	1999-09-10
WO1996015146A1 (en)	1996-05-23
KR100253762B1 (ko)	2000-05-01
AU694589B2 (en)	1998-07-23
CZ137597A3 (cs)	1998-10-14
DK0792288T3 (da)	1999-09-13
US5770577A (en)	1998-06-23
EP0792288B1 (de)	1999-01-20
ATE175973T1 (de)	1999-02-15
GR3029790T3 (en)	1999-06-30
DE69507507D1 (de)	1999-03-04

Legal Events

Date	Code	Title	Description
2003-06-30	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO972176L (no)	1997-07-14	Konjugater av BDNF og NT-3 med en vannopplöselig polymer
MXPA97003362A (en)	1997-08-01	Conjugates of bdnf and nt-3 with a polymer solubleen a
JP5241037B2 (ja)	2013-07-17	截形グリア細胞系由来神経栄養因子
AU615810B2 (en)	1991-10-10	Osteogenic factors
SK1499A3 (en)	1999-08-06	Analogs of cationic proteins
BG62975B1 (bg)	2000-12-29	Рекомбинантни протеини на затлъстяването
US20160060317A1 (en)	2016-03-03	Novel neurturin conjugates for pharmaceutical use
CN101627056B (zh)	2013-05-15	Y型聚乙二醇修饰的g-csf及其制备方法和应用
CA2113206A1 (en)	1993-02-04	Modified pf4 compositions and methods of use
EP0409727A2 (de)	1991-01-23	Reinigung des Nervenwachstumfaktors (beta Unterteil) durch Unterteilsaustauschchromatographie
JPH05238941A (ja)	1993-09-17	薬剤組成物
CN117462652A (zh)	2024-01-30	gp96及其在治疗肌萎缩侧索硬化的用途
CA2079291A1 (en)	1993-03-31	Activities of heparin binding neurite-outgrowth promoting factor